Toleranzia AB (OSTO:TOL) Other Gross PPE : kr0.00 Mil (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Toleranzia AB Other Gross PPE?

Toleranzia AB's Other Gross PPE for the quarter that ended in Sep. 2024 was kr0.00 Mil.

Toleranzia AB's annual Other Gross PPE declined from Dec. 2021 (kr0.22 Mil) to Dec. 2022 (kr0.00 Mil) but then stayed the same from Dec. 2022 (kr0.00 Mil) to Dec. 2023 (kr0.00 Mil).

Toleranzia AB Other Gross PPE Historical Data

The historical data trend for Toleranzia AB's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Toleranzia AB Other Gross PPE Chart

Toleranzia AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Gross PPE

Get a 7-Day Free Trial

0.22

Toleranzia AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Gross PPE	Get a 7-Day Free Trial															-	-	-	-	-

Toleranzia AB Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Toleranzia AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Toleranzia AB (OSTO:TOL) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

N/A

Address

Arvid Wallgrens backe 20, 8th floor, Gothenburg, SWE, SE-413 46

Website

https://www.toleranzia.com

Toleranzia AB is a Swedish biotechnology Company. The company develops drugs that harness the power of the immune system to treat autoimmune orphan diseases The company's drug candidate, TOL2, is being developed for the treatment of the autoimmune neuromuscular disease myasthenia gravis, an orphan disease.